Article

Drugs, Biologics, and Devices

Lewis Grossman

in The Oxford Handbook of U.S. Health Law

Published in print January 2017 | ISBN: 9780199366521
Published online July 2015 | e-ISBN: 9780199366545 | DOI: https://dx.doi.org/10.1093/oxfordhb/9780199366521.013.30

Series: Oxford Handbooks

Drugs, Biologics, and Devices

More Like This

Show all results sharing these subjects:

  • Medical and Healthcare Law
  • Intellectual Property Law

GO

Show Summary Details

Preview

This article examines the basic framework of the U.S. Food and Drug Administration (FDA)’s approval process for drugs, biologics, and medical devices within the broader context of the country’s healthcare system. The article also discusses intellectual property protections and statutory exclusivity periods for medical products and their effect on the market entry of follow-on therapies. It then considers a number of current developments shaping FDA regulation of pharmaceuticals and medical devices, including the rise of personalized medicine, the strengthening of First Amendment commercial speech protections, and the agency’s expanding involvement in the practice of medicine. Finally, the article examines how the FDA must increasingly share its gatekeeping role with third-party payers and considers the agency’s future in light of this phenomenon.

Keywords: Food and Drug Administration; drugs; biologics; medical devices; healthcare; intellectual property; exclusivity periods; market entry; medical products; regulation

Article.  11152 words. 

Subjects: Medical and Healthcare Law ; Intellectual Property Law

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.